Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (Stock Code: ) Releases Preliminary 2025 Annual Results

Bulletin Express

Feb 27

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. reported revenue of RMB 685.80 million for the year ended December 31, 2025, reflecting a slight decline compared with the previous year. Operating profit recorded approximately RMB -155.40 million, and net profit attributable to ordinary shareholders stood at around RMB -157.44 million. According to the announcement, the company's research and development investments amounted to roughly RMB 358.00 million for the reporting period.

The decrease in profitability was largely influenced by adjustments to the sales strategy of its product LIBOd®, which reduced profit contributions by about RMB 100.00 million compared with the prior year. At the same time, higher R&D expenses—an increase of around RMB 44.00 million—impacted earnings. The announcement states that these figures are based on unaudited results and that final audited numbers will be disclosed in the official annual report.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1142365130"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142365130\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142365130?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 18:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142365130","market":"us","top_or_hot":-1,"title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (Stock Code: ) Releases Preliminary 2025 Annual Results","media":"Bulletin Express","content":"<p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. reported revenue of RMB 685.80 million for the year ended December 31, 2025, reflecting a slight decline compared with the previous year. Operating profit recorded approximately RMB -155.40 million, and net profit attributable to ordinary shareholders stood at around RMB -157.44 million. According to the announcement, the company's research and development investments amounted to roughly RMB 358.00 million for the reporting period.</p>\n<p>The decrease in profitability was largely influenced by adjustments to the sales strategy of its product LIBOd®, which reduced profit contributions by about RMB 100.00 million compared with the prior year. At the same time, higher R&D expenses—an increase of around RMB 44.00 million—impacted earnings. The announcement states that these figures are based on unaudited results and that final audited numbers will be disclosed in the official annual report.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (Stock Code: ) Releases Preliminary 2025 Annual Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Fudan-Zhangjiang Bio-Pharmaceutical (Stock Code: ) Releases Preliminary 2025 Annual Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-27 18:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. reported revenue of RMB 685.80 million for the year ended December 31, 2025, reflecting a slight decline compared with the previous year. Operating profit recorded approximately RMB -155.40 million, and net profit attributable to ordinary shareholders stood at around RMB -157.44 million. According to the announcement, the company's research and development investments amounted to roughly RMB 358.00 million for the reporting period.</p>\n<p>The decrease in profitability was largely influenced by adjustments to the sales strategy of its product LIBOd®, which reduced profit contributions by about RMB 100.00 million compared with the prior year. At the same time, higher R&D expenses—an increase of around RMB 44.00 million—impacted earnings. The announcement states that these figures are based on unaudited results and that final audited numbers will be disclosed in the official annual report.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01349","symbol_name":"复旦张江","start_time":0,"source_url":"","article_id":"1142365130","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142365130","pubTimestamp":1772188884,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. reported revenue of RMB 685.80 million for the year ended December 31, 2025, reflecting a slight decline compared with the previous year....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01349":"复旦张江"},"translate_title":"上海复旦张江生物制药（股票代码：）发布2025年度初步业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01349":1},"content_text":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. reported revenue of RMB 685.80 million for the year ended December 31, 2025, reflecting a slight decline compared with the previous year. Operating profit recorded approximately RMB -155.40 million, and net profit attributable to ordinary shareholders stood at around RMB -157.44 million. According to the announcement, the company's research and development investments amounted to roughly RMB 358.00 million for the reporting period.\nThe decrease in profitability was largely influenced by adjustments to the sales strategy of its product LIBOd®, which reduced profit contributions by about RMB 100.00 million compared with the prior year. At the same time, higher R&D expenses—an increase of around RMB 44.00 million—impacted earnings. The announcement states that these figures are based on unaudited results and that final audited numbers will be disclosed in the official annual report.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}